Brentuximab vedotin-nivolumab regimen induces response in limited-stage Hodgkin lymphoma

ByAshley Killen

ByTatyana Feldman, MD

Fact checked byMindy Valcarcel, MS

NEW ORLEANS — Induction with brentuximab vedotin plus AVD chemotherapy followed by nivolumab consolidation exhibited encouraging activity among previously untreated patients with limited-stage non-bulky Hodgkin lymphoma, according to study results.

Nearly all patients achieved negative interim PET after an abbreviated course of brentuximab vedotin (Adcetris, Seagen) and chemotherapy, findings of the ACCRU-LY1601 study presented at ASH Annual Meeting and Exposition showed. All patients remained progression free after nivolumab (Opdivo, Bristol Myers Squibb) consolidation after median follow-up of 22 months.

Healio spoke with researcher Tatyana Feldman, MD, director of the T-cell lymphoma program at Hackensack Meridian John Theurer Cancer Center, about the results and their potential implications.

Published by:

Sources/Disclosures

Collapse

Source:

Park SI, et al. Abstract 728. Presented at: ASH Annual Meeting and Exposition; Dec. 10-13, 2022; New Orleans.

Disclosures: Feldman reports consulting/advisory roles with, speakers bureau roles with or other financial relationships with AbbVie, ADC Therapeutics, AstraZeneca, Bristol Myers Squibb, Celgene, Daiichi Sankyo, Genmab, Genomic Testing Cooperative, Janssen, Karyopharm Therapeutics, Kite Pharma, MorphoSys, Pharmacyclics, Secura Bio, Seagen and Takeda. Please see the abstract for all other researchers’ relevant financial disclosures.

ASH Annual Meeting and Exposition

Read more

Brentuximab vedotin-nivolumab regimen induces response in limited-stage Hodgkin lymphoma

Related Content